Spero Therapeutics and partner GSK received FDA approval for Utebzi, the first oral carbapenem treatment for complicated urinary tract infections. This approval positions Spero to earn milestone payments and royalties from GSK, with potential annual revenues around $50 million and further upside if Utebzi becomes a blockbuster drug. Despite recent stock volatility and a limited drug pipeline, Spero's low cash burn and funding runway through 2028 support a positive outlook for risk-tolerant investors. Analyst Edmund Ingham initiates coverage with a Buy rating, viewing the stock as undervalued relative to its future revenue potential but notes the investment carries high risk and uneven returns.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
